On the evening of January 16, 140000 investors suffered bad luck.
One is that the Kaile Science And Technology Co.Ltd.Hubei(600260) vice chairman and general manager was taken retention measures. Six months ago, the private network communication business of the stock exploded, resulting in huge losses, and the share price has plummeted by more than 66%.
One is that the trading of covid-19 special drug Daniu stock Aba Chemicals Corporation(300261) was suspended again after a sharp rise of 300% in one month.
Aba Chemicals Corporation(300261) suspension
soared by more than 300% in one month
It was announced at Aba Chemicals Corporation(300261) on the afternoon of January 16 that the deviation of the closing price increase of the company for two consecutive trading days on January 13 and January 14, 2022 reached more than 30%. According to relevant regulations, it belongs to abnormal fluctuation of stock trading. According to relevant regulations, the company will verify the abnormal fluctuation of stock trading. The trading of the company’s shares will be suspended from the opening of the market on January 17, 2022 and resumed after the disclosure of the verification announcement.
According to the announcement, the deviation of the closing price increase of the company for two consecutive trading days has reached 30%, which is in line with the abnormal fluctuation of stock trading in Shenzhen Stock Exchange.
In fact, since December 20, Aba Chemicals Corporation(300261) share price has started the soaring mode. By the closing on January 14, the company’s share price has soared by more than 300% in one month.
Shenzhen Stock Exchange: key monitoring
Before the suspension, the Shenzhen Stock Exchange released the market trading supervision trends on Friday. From January 10 to January 14, the Shenzhen Stock Exchange adopted self-discipline supervision measures for 87 abnormal securities trading behaviors, involving abnormal trading situations such as intraday lifting and suppression and false declaration; Focus on monitoring ” Aba Chemicals Corporation(300261) ” with abnormal recent increase; A total of 9 major events of listed companies were verified and reported to the CSRC for clues of one suspected case of violation of laws and regulations.
According to the data, Aba Chemicals Corporation(300261) belongs to covid-19 specific drug concept unit. On December 3, 2021, China International Capital Corporation Limited(601995) chemical team published the report “pay attention to Pfizer covid-19 Drug Intermediates – isopentenol and inulin” in the journal Science. The research results show that carbonic anhydride and its derivatives can be used to synthesize Pfizer covid-19 oral drug palovide from the process flow.
While Aba Chemicals Corporation(300261) has a patent for the synthesis of carbonic anhydride, there are other synthetic processes for the synthesis of carbonic anhydride.
At that time, the epidemic situation outside China was repeated, and the hype of covid-19 specific drugs was booming. Aba Chemicals Corporation(300261) has a special and synthetic process for the synthesis of carbonic anhydride. After a period of fermentation, the stock price of Aba Chemicals Corporation(300261) began to change on December 20.
has been suspended for verification once before
clarify two benefits
In fact, this is not the first time that the company has been suspended for verification due to stock changes recently.
On December 28, 2021, Aba Chemicals Corporation(300261) announced that it was suspended for verification due to changes. At that time, Aba Chemicals Corporation(300261) rose 160% in seven trading days, including the “20cm” limit in four trading days.
At that time, the two news triggered a sharp rise in the company’s share price. One is Aba Chemicals Corporation(300261) recently said that the main structure of CBD medical product production workshop under Malta subsidiary has been basically completed. At present, equipment installation and application for GMP certification are under way. Cannabinoid is a pure natural component extracted from cannabis plant.
Second, it is rumored that Aba Chemicals Corporation(300261) has a cooperative relationship with Pfizer, mainly pointing out that Aba Chemicals Corporation(300261) supplies carlon anhydride and its derivatives to Pfizer.
This has also attracted regulatory attention. Subsequently, the company suspended its trading and clarified:
1. As of the reply date of this letter of concern, the company has not signed any cooperation agreement with Pfizer, has no cooperative relationship with Pfizer, and has not supplied carlon anhydride and its derivatives to Pfizer. As of the reply date of this letter of concern, the sales revenue of the company’s carbonic anhydride and its derivatives is 27.073 million yuan, accounting for about 1% – 2% of the company’s total operating revenue in 2021, which is relatively small. It is not expected to have a significant impact on the company’s performance in 2021 and 2022. If the downstream demand of the company’s carbonic anhydride and its derivatives decreases in the future, or the supply of other manufacturers in the industry increases significantly, the product supply may exceed the demand, which may have an adverse impact on the company’s operation and performance.
2. As of the reply date of this letter of concern, the main structure of a2w CBD medical product production workshop has been basically completed, equipment installation and application for GMP certification are under way, and no CBD medical products have been produced and sold this year. Affected by the epidemic in Europe, the company expects that the CBD medical products of a2w will be officially put into operation in the first quarter of 2023, and will not bring any sales revenue and profit contribution to the company in 2021 and 2022, and will not have a significant impact on the financial and operating conditions of the company in 2021 and 2022. If the overseas epidemic continues to spread, the construction progress of a2w production workshop may be less than expected; The GMP certification process of a2w is uncertain, which may affect the production progress of CBD medical products; If the supply and demand situation of CBD market changes in the future, it will have an adverse impact on the project; A2w is a newly established overseas company, which may face market risks, changes in national policies and other risks in the actual operation process.
Subsequently, trading resumed on January 5, 2022.
However, after the resumption of trading, the stock quickly returned to the soaring mode after adjusting for two days: after the limit fell on January 7, the stock began to rise again on January 8 and again on January 14. So far, the rise rate in five trading days has reached 81.53%.
hot money, cattle scattered fighting
40000 investors cried: they were buried alive as soon as they chased the high
Now the trading is suspended again. Many retail investors chasing high cry in the stock bar: they were buried alive as soon as they chased high.
Data show that as of December 20, the number of shareholders of the stock was nearly 40000.
It is worth noting that many investors mentioned that they fought with the funds of niusan “Fang Xinxia”.
According to the recent list of dragons and tigers, top hot money such as “Xu Liusheng”, “Fang Xinxia” and “Shanghai Liyang road” have participated in it. For example, Niu Sanfang Xinxia, who often used the seat of China Industrial Securities Co.Ltd(601377) Shaanxi Branch, bought more than 37.2 million yuan on December 27.
On January 14, it bought nearly 87 million yuan.
Kaile Science And Technology Co.Ltd.Hubei(600260) the vice chairman was taken retention measures
At the same time, Kaile Science And Technology Co.Ltd.Hubei(600260) announced that Zhu Junlin, vice chairman and general manager of the company, was detained by the Shifeng District Supervision Committee of Zhuzhou City, Hunan Province on suspicion of serious violations.
During this period, Mr. Ma Shengjun, vice chairman of the company, performed the duties of the general manager on his behalf.
Perhaps because the announcement was too hasty, the “vice chairmen” of the two places were wrong.
100000 investors were stunned: the previous thunder burst
“wearing a hat”, huge losses, and a sharp decline of more than 66% in half a year
As soon as the news came out, Kaile Science And Technology Co.Ltd.Hubei(600260) stock bar quickly fried the pot, and many investors said it was thunder.
It is worth noting that half a year ago, Kaile technology announced that the private network communication business exploded, that is, Sui Tianli’s “private network communication” scam shocked the market at that time. Then the share price fell endlessly.
On the evening of July 23, 2021, Keller Technology issued a major risk warning for the first time, saying that the balance of prepayment for the company’s private network communication business was RMB 6.227 billion, including the overdue supply contract amount of upstream suppliers of RMB 1.151 billion, and the company has filed a lawsuit.
On the same day, Kaile technology announced that the Shanghai Stock Exchange issued a supervision letter, requiring Kaile technology to verify the private network communication business model, business essence, upstream and downstream relationships, capital and goods exchanges, current development, and whether there are major adverse changes as soon as possible, carefully figure out and evaluate various risk exposures, and make announcements in a timely, comprehensive and accurate manner.
On the evening of August 15, 2021, Kaile Science And Technology Co.Ltd.Hubei(600260) disclosed that due to the suspension of private network communication business, it is expected that it will not be restored in the short term. The company’s stock will implement other risk warnings from August 17, and the stock abbreviation will be changed from “Kaile technology” to ” Kaile Science And Technology Co.Ltd.Hubei(600260) “.
As of the announcement, the prepayment of Kaile Science And Technology Co.Ltd.Hubei(600260) private network communication business is 6.227 billion yuan, the accounts receivable is 52 million yuan, the inventory is 218 million yuan, the overdue supply contract amount is 4.514 billion yuan (according to the amount of purchase contract signed), and the remaining 1.713 billion yuan contract has the risk that the overdue supply and prepayment cannot be recovered in full.
Kaile Science And Technology Co.Ltd.Hubei(600260) shares have fallen more than 66% since July. As of the latest, the share price of the stock is 2.77 yuan per share, with a market value of only 2.8 billion yuan.
At the same time, the company’s performance was also seriously dragged down, with a net profit loss of more than 6 billion yuan in the first three quarters of 2021. It is worth mentioning that Kaile Science And Technology Co.Ltd.Hubei(600260) also announced recently that it was unable to return about 200 million yuan of raised funds on schedule.
